【摘要】 目的 从多维度对治疗慢性呼吸系统疾病的13种吸入制剂进行综合评价，为医疗机构药物遴选及临床合理用药提供参考。方法 以指南制定的百分制评估体系为基础，查阅药品说明书，检索维普、中国知网、万方、PubMed、UpToDate等数据库中的诊疗指南、文献等，从安全性、有效性、创新性、经济性、其他属性、附加项6个维度和24个二级指标对河北省药品和医用耗材招采管理系统挂网的13种吸入制剂进行量化赋值，依据评分结果划分推荐级别。结果 量化评分结果依次为硫酸沙丁胺醇吸入气雾剂78.7分，氟替美维吸入粉雾剂74分，沙美特罗替卡松吸入粉雾剂73.5分，布地格福吸入气雾剂72.8分，为强推荐（≥70分）；噻托溴铵吸入粉雾剂64.7分，布地奈德福莫特罗粉吸入剂62.5分，格隆溴铵福莫特罗吸入气雾剂62.1分，为弱推荐（≥60分，<70分）；乌美溴铵维兰特罗吸入粉雾剂58分，茚达特罗莫米松吸入粉雾剂57.2分，茚达特罗格隆溴铵吸入粉雾剂56.2分，倍氯米松福莫特罗吸入气雾剂55.8分，噻托溴铵吸入喷雾剂54.8分，马来酸茚达特罗吸入粉雾剂52.2分，为不推荐（<60分）。结论 医疗机构可参考本研究的量化评分结果快速遴选吸入制剂品种。更多还原

【Abstract】 Objective To comprehensively evaluate 13 inhalation formulations for the treatment of chronic respiratory diseases from multiple dimensions, providing reference for drug selection and rational clinical use in medical institutions. Methods Based on the 100-point evaluation system developed according to the guidelines, the package inserts were looked up, and the relevant diagnosis and treatment guidelines and literature were searched for in databases such as VIP, CNKI, Wanfang, PubMed, UpToDate, etc.. From six dimensions of safety, effectiveness, innovation, economy, other attributes, and additional items, 24 secondary indicators were used to quantitatively assign values to the 13 inhalation preparations listed on the Hebei Province Drug and Medical Consumables Procurement Management System. Based on the scoring results, recommendation levels were divided. Results The quantitative scoring results were as follows: salbutamol sulfate inhalation aerosol scored 78. 7 points, fluoxetine inhalation powder scored 74 points, salmeterol and fluticasone inhalation powder scored 73. 5 points, and budesonide inhalation aerosol scored 72. 8 points, all of which were strongly recommended（≥70 points）; the inhalation powder of tiotropium bromide scored 64. 7 points, budesonide formoterol powder inhalation scored 62. 5 points, and the inhalation aerosol of glycopyrronium and formoterol scored 62. 1 points, all of which were weakly recommended （≥60 points and <70 points）; umeclidinium vilanterol powder inhalation scored 58 points, indacaterol mometasone powder inhalation scored 57. 2 points, indacaterol and glycopyrronium powder inhalation scored 56. 2 points, beclometasone formoterol powder inhalation scored 55. 8 points, tiotropium bromide inhalation spray scored 54. 8 points, and indacaterol maleate powder inhalation scored 52. 2 points, all of which were not recommended(<60 points). Conclusion Medical institutions can refer to the quantitative scoring results of this study to quickly select inhalation formulations.更多还原